Zentalis Pharmaceuticals (ZNTL) Amortizatization of Intangibles (2020 - 2026)

Zentalis Pharmaceuticals' Amortizatization of Intangibles history runs 7 years deep, the most recent figure standing at $224000.0 for Q1 2026.

• On a quarterly basis, Amortizatization of Intangibles fell 78.34% year-over-year to $224000.0 in Q1 2026; TTM through Mar 2026 was $2.0 million, a 68.86% decrease from a year earlier, with the FY2025 full-year figure at $2.8 million, down 65.47% from the prior year.
• Amortizatization of Intangibles slipped to $224000.0 in Q1 2026 per ZNTL's latest filing, from $431000.0 in the prior quarter.
• Across five years, Amortizatization of Intangibles topped out at $4.6 million in Q4 2023 and bottomed at -$146000.0 in Q1 2022.
• The 5-year median for Amortizatization of Intangibles is $1.4 million (2024), against an average of $1.6 million.
• Across the five-year window, Amortizatization of Intangibles tumbled 150.52% in 2022 and surged 2397.67% in 2023, its largest moves.
• Year by year, Amortizatization of Intangibles stood at $2.5 million in 2022, then soared by 83.97% to $4.6 million in 2023, then tumbled by 69.33% to $1.4 million in 2024, then plunged by 69.15% to $431000.0 in 2025, then plunged by 48.03% to $224000.0 in 2026.
• Per Business Quant, the three latest ZNTL Amortizatization of Intangibles figures stand at $224000.0 (Q1 2026), $431000.0 (Q4 2025), and $517000.0 (Q3 2025).